Gastric Emptying Research Peptides

4 research peptides demonstrate gastric emptying properties. This collection covers their mechanisms, evidence base, and research applications.

FDA Approved | Metabolic / GLP-1 Agonist

Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA, with Byetta (twice-daily injection) approved in April 2005 and Bydureon (once-weekly extended-release) approved in January 2012, both for type 2 diabetes. Exenatide shares approximately 53% sequence homology with human GLP-1 and is resistant to DPP-4 degradation.

Mechanism: Exenatide binds to and activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It suppresses inappropriately elevated glucagon secretion, slows gastric emptying, and reduces food intake through central appetite regulation. Unlike human GLP-1, exenatide is resistant to degradation by dipeptidyl peptidase-4 (DPP-4) due to a glycine substitution at position 2. The immediate-release formulation (Byetta) has a half-life of approximately 2.4 hours, while the extended-release formulation (Bydureon) uses poly(D,L-lactide-co-glycolide) microspheres to provide sustained release over one week. Exenatide is primarily eliminated by glomerular filtration with subsequent proteolytic degradation.

FDA Approved | Metabolic / GLP-1 Agonist

Lixisenatide is a once-daily GLP-1 receptor agonist (MW ~4858.5 g/mol) based on the exendin-4 scaffold, with a modified C-terminal tail containing six lysine residues. It is also marketed as Lyxumia outside the United States. Lixisenatide is available in a fixed-ratio combination with insulin glargine as Soliqua 100/33.

Mechanism: Lixisenatide is a 44-amino-acid peptide that activates the GLP-1 receptor with high affinity. It is derived from exendin-4 with deletion of a proline residue and addition of six C-terminal lysine residues, which enhance resistance to DPP-4 degradation. As a prandial (short-acting) GLP-1 agonist, lixisenatide has a half-life of approximately 3 hours and predominantly reduces postprandial glucose through potent slowing of gastric emptying, in addition to stimulating glucose-dependent insulin secretion and suppressing glucagon. Its short-acting profile provides stronger postprandial glucose reduction relative to fasting glucose reduction, distinguishing it from longer-acting GLP-1 agonists. Eliminated through glomerular filtration, tubular reabsorption, and metabolic catabolism.

FDA Approved | Metabolic / Amylin Analog

Pramlintide (brand name Symlin) is a synthetic analog of amylin, a 37-amino-acid pancreatic hormone co-secreted with insulin from beta cells (MW ~3949.4 g/mol). Pramlintide has three proline substitutions (positions 25, 28, 29) that prevent the amyloid aggregation inherent to native human amylin.

Mechanism: Pramlintide mimics the actions of endogenous amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells in response to meals. It binds to amylin receptors (calcitonin receptor/RAMP complexes) in the area postrema and other brain regions. Its three key pharmacological actions are: (1) slowing gastric emptying, extending nutrient absorption; (2) suppressing postprandial glucagon secretion (which is inappropriately elevated in diabetes); and (3) promoting satiety through central nervous system signaling, reducing caloric intake. Three proline substitutions at positions 25, 28, and 29 (modeled after rat amylin, which naturally has prolines at these positions) prevent the beta-sheet aggregation and amyloid fibril formation that make native human amylin unsuitable as a drug. Half-life is approximately 48 minutes. Metabolized primarily by the kidneys.

Phase III / NDA Filed | Metabolic / Endogenous Hormone

Amylin (islet amyloid polypeptide, IAPP) is an endogenous 37-amino-acid peptide hormone (MW ~3903.3 g/mol) co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. It plays a key role in postprandial glucose regulation by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety. Amylin is deficient in type 1 diabetes and relatively deficient in advanced type 2 diabetes. While amylin itself is not used as a drug due to its propensity to form amyloid fibrils, it is the basis for the approved analog pramlintide (Symlin) and the investigational long-acting analog cagrilintide.

Mechanism: Amylin is synthesized as an 89-amino-acid preprohormone in pancreatic beta cells and processed to its mature 37-amino-acid form with a C-terminal amide and an intramolecular disulfide bond between Cys-2 and Cys-7. It is co-packaged with insulin in secretory granules and released in a roughly 1:100 molar ratio (amylin:insulin). Amylin acts through amylin receptors, which are heteromeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Key target areas include the area postrema (gastric emptying, nausea), hypothalamus (satiety, energy expenditure), and pancreatic alpha cells (glucagon suppression). Human amylin has a strong tendency to misfold into beta-sheet-rich amyloid fibrils, which are found in pancreatic islet deposits in approximately 90% of type 2 diabetes patients at autopsy. This aggregation propensity makes native amylin unsuitable as a therapeutic agent. Half-life of circulating amylin is approximately 13 minutes. Cleared primarily by renal peptidases.